Cargando…

Risk for primary cephalosporin resistance in Gram-negative bacteremia

OBJECTIVE: This study aimed to examine the clinical risk factors for cephalosporin resistance in patients with Gram-negative bacteremia caused by Escherichia coli (EC), Klebsiella pneumoniae (KP), Enterobacter cloacae (ENC), and Pseudomonas aeruginosa (PS). METHODS: This retrospective cohort study i...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Princy, Shahbazian, Sona, Lainhart, William D., Hayes, Justin, Mochon, Brian, Nix, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369432/
https://www.ncbi.nlm.nih.gov/pubmed/37502246
http://dx.doi.org/10.1017/ash.2023.202
_version_ 1785077759590006784
author John, Princy
Shahbazian, Sona
Lainhart, William D.
Hayes, Justin
Mochon, Brian
Nix, David E.
author_facet John, Princy
Shahbazian, Sona
Lainhart, William D.
Hayes, Justin
Mochon, Brian
Nix, David E.
author_sort John, Princy
collection PubMed
description OBJECTIVE: This study aimed to examine the clinical risk factors for cephalosporin resistance in patients with Gram-negative bacteremia caused by Escherichia coli (EC), Klebsiella pneumoniae (KP), Enterobacter cloacae (ENC), and Pseudomonas aeruginosa (PS). METHODS: This retrospective cohort study included 400 adults with Gram-negative bacteremia. The goal was to review 100 cases involving each species and approximately half resistant and half susceptible to first-line cephalosporins, ceftriaxone (EC or KP), or cefepime (ENC or PS). Logistic regression was used to identify factors predictive of resistance. RESULTS: A total of 378 cases of Gram-negative bacteremia were included in the analysis. Multivariate analysis identified significant risk factors for resistance, including admission from a chronic care hospital, skilled nursing facility, or having a history of infection within the prior 6 months (OR 3.00, P < .0001), requirement for mechanical ventilation (OR 3.76, P < .0001), presence of hemiplegia (OR 3.54, P = .0304), and presence of a connective tissue disease (OR 3.77, P = .0291). CONCLUSIONS: Patients without the identified risk factors should be strongly considered for receiving ceftriaxone or cefepime rather than carbapenems and newer broad-spectrum agents.
format Online
Article
Text
id pubmed-10369432
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-103694322023-07-27 Risk for primary cephalosporin resistance in Gram-negative bacteremia John, Princy Shahbazian, Sona Lainhart, William D. Hayes, Justin Mochon, Brian Nix, David E. Antimicrob Steward Healthc Epidemiol Original Article OBJECTIVE: This study aimed to examine the clinical risk factors for cephalosporin resistance in patients with Gram-negative bacteremia caused by Escherichia coli (EC), Klebsiella pneumoniae (KP), Enterobacter cloacae (ENC), and Pseudomonas aeruginosa (PS). METHODS: This retrospective cohort study included 400 adults with Gram-negative bacteremia. The goal was to review 100 cases involving each species and approximately half resistant and half susceptible to first-line cephalosporins, ceftriaxone (EC or KP), or cefepime (ENC or PS). Logistic regression was used to identify factors predictive of resistance. RESULTS: A total of 378 cases of Gram-negative bacteremia were included in the analysis. Multivariate analysis identified significant risk factors for resistance, including admission from a chronic care hospital, skilled nursing facility, or having a history of infection within the prior 6 months (OR 3.00, P < .0001), requirement for mechanical ventilation (OR 3.76, P < .0001), presence of hemiplegia (OR 3.54, P = .0304), and presence of a connective tissue disease (OR 3.77, P = .0291). CONCLUSIONS: Patients without the identified risk factors should be strongly considered for receiving ceftriaxone or cefepime rather than carbapenems and newer broad-spectrum agents. Cambridge University Press 2023-07-10 /pmc/articles/PMC10369432/ /pubmed/37502246 http://dx.doi.org/10.1017/ash.2023.202 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Original Article
John, Princy
Shahbazian, Sona
Lainhart, William D.
Hayes, Justin
Mochon, Brian
Nix, David E.
Risk for primary cephalosporin resistance in Gram-negative bacteremia
title Risk for primary cephalosporin resistance in Gram-negative bacteremia
title_full Risk for primary cephalosporin resistance in Gram-negative bacteremia
title_fullStr Risk for primary cephalosporin resistance in Gram-negative bacteremia
title_full_unstemmed Risk for primary cephalosporin resistance in Gram-negative bacteremia
title_short Risk for primary cephalosporin resistance in Gram-negative bacteremia
title_sort risk for primary cephalosporin resistance in gram-negative bacteremia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369432/
https://www.ncbi.nlm.nih.gov/pubmed/37502246
http://dx.doi.org/10.1017/ash.2023.202
work_keys_str_mv AT johnprincy riskforprimarycephalosporinresistanceingramnegativebacteremia
AT shahbaziansona riskforprimarycephalosporinresistanceingramnegativebacteremia
AT lainhartwilliamd riskforprimarycephalosporinresistanceingramnegativebacteremia
AT hayesjustin riskforprimarycephalosporinresistanceingramnegativebacteremia
AT mochonbrian riskforprimarycephalosporinresistanceingramnegativebacteremia
AT nixdavide riskforprimarycephalosporinresistanceingramnegativebacteremia